Why hasn't neuroprotection worked in Parkinson's disease?

Nature Clinical Practice Neurology

Volumn 3, Issue 5, 2007, Pages 240-241

  Kieburtz, Karl ^a   Ravina, Bernard ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CEP 1347; NEUROPROTECTIVE AGENT; RASAGILINE; RILUZOLE; SELEGILINE; TCH 346; UBIDECARENONE; UNCLASSIFIED DRUG;

CELL DEATH; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DOPAMINE DEFICIENT MOUSE; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; EXPERIMENTATION; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANIMALS; APOPTOSIS; CELL SURVIVAL; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 34248524675     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0491     Document Type: Review

References (9)

1. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early PD. N Engl J Med 321: 1364-1371
2. Palhagen S et al. (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66: 1200-1206
3. Rascol O et al. (2002) A 2-year multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 17 (Suppl 5): S39
4. Shults CW et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 59: 1541-1550
5. Olanow CW et al. (2006) TCH346 as a neuroprotective drug in Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 5: 1013-1020
6. Shoulson I et al. (2006) CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study [abstract #S61.003]. Neurology 67: A185
7. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of Rasagiline in early Parkinson disease. Arch Neurol 61 561-566
8. Ravina B et al. (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64: 208-215
9. NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66: 664-671